[P3-57] Neurological Complications Associated With Busulfan Conditioning Therapy Before Stem Cell Transplantation In Children, A Retrospective Tertiary Center Experience
[Introduction]:
Stem cell transplantation(SCT) is an important modality of treatment in hematologic and neurologic diseases. Busulfan(BFN) is a chemotherapy used in conditioning therapy prior to SCT. BFN is well known to cause systemic and neurologic side effects including seizures. Antiepileptic drugs(AED) are used to prevent seizures.
We aim to Review clinical and neurological outcome after using BFN Pre-SCT and to identify potential risk factors which may contribute to neurotoxicity in patients receiving BFN.
[Methodology]:
After obtaining ethical approval, a retrospective files reviewed for patients who underwent SCT from 2010 until 2015, from the transplant registry. Multiple variables were analyzed including demographic, clinical, laboratory data and imaging. All pediatric patients aged from 1 month to 14 years in the period from 1/1/2010 to 31/12/2015 will be included. All records with incomplete data will be excluded.
[Results]:
429 cases were identified. 8 patients were excluded from the study due to incomplete data. 6 patients had seizure related to BFN(1.4%), and 9 had seizure related to SCT complication(2%). All patients received BFN over 4 days and phenytoin prophylaxis over 6 days. Those who had seizure, received additional levetiracetam. No major side effects to phenytoin were recorded. This is an ongoing approved project.
[Conclusions]:
Busulfan associated seizure is uncommon with the use of AED prophylaxis. It appears safe.
[Ethics Statement]:
The study was done in accordance with the Declaration of Helsinki (1975, as revised in 2008) and has got approval by the ethics committee of our hospital. All study participants provided written informed consent.
Stem cell transplantation(SCT) is an important modality of treatment in hematologic and neurologic diseases. Busulfan(BFN) is a chemotherapy used in conditioning therapy prior to SCT. BFN is well known to cause systemic and neurologic side effects including seizures. Antiepileptic drugs(AED) are used to prevent seizures.
We aim to Review clinical and neurological outcome after using BFN Pre-SCT and to identify potential risk factors which may contribute to neurotoxicity in patients receiving BFN.
[Methodology]:
After obtaining ethical approval, a retrospective files reviewed for patients who underwent SCT from 2010 until 2015, from the transplant registry. Multiple variables were analyzed including demographic, clinical, laboratory data and imaging. All pediatric patients aged from 1 month to 14 years in the period from 1/1/2010 to 31/12/2015 will be included. All records with incomplete data will be excluded.
[Results]:
429 cases were identified. 8 patients were excluded from the study due to incomplete data. 6 patients had seizure related to BFN(1.4%), and 9 had seizure related to SCT complication(2%). All patients received BFN over 4 days and phenytoin prophylaxis over 6 days. Those who had seizure, received additional levetiracetam. No major side effects to phenytoin were recorded. This is an ongoing approved project.
[Conclusions]:
Busulfan associated seizure is uncommon with the use of AED prophylaxis. It appears safe.
[Ethics Statement]:
The study was done in accordance with the Declaration of Helsinki (1975, as revised in 2008) and has got approval by the ethics committee of our hospital. All study participants provided written informed consent.